Complement dysregulation in AD is further supported by human biomarker studies of CSF and plasma, with consistent changes in C3, C4, C1q, TCC, and Factor H confirming the translational significance of complement-targeted mechanisms [176, 321, 437]. Here, CFH is linked to Alzheimer disease.